Status and phase
Conditions
Treatments
About
Phase 1, open-label study of BHV-0223 in ALS.
Full description
This is a phase 1, open-label, single arm study to evaluate the safety, tolerability and pharmacokinetics of multiple doses of BHV-0223 in subjects with ALS.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Target Disease Exceptions
Medical History Exceptions
Physical and Laboratory Test Findings
Other Exclusions a. Subjects who are unable to be compliant with the visit schedule or protocol procedures.
Primary purpose
Allocation
Interventional model
Masking
22 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal